Abstract
Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.
| Original language | English |
|---|---|
| Pages (from-to) | 628-632 |
| Number of pages | 5 |
| Journal | Journal of Hepato-Biliary-Pancreatic Surgery |
| Volume | 16 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2009 Jun 25 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Hepatology
Cite this
}
Drug-eluting stent in malignant biliary obstruction. / Lee, DongKi.
In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 16, No. 5, 25.06.2009, p. 628-632.Research output: Contribution to journal › Article
TY - JOUR
T1 - Drug-eluting stent in malignant biliary obstruction
AU - Lee, DongKi
PY - 2009/6/25
Y1 - 2009/6/25
N2 - Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.
AB - Introduction: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice. However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect. Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored. Material and methods: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract. The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia. For example, the non-vascular stent might be covered with a membrane that gradually releases a chemo-agent. We do not have much experience with DES in the bile duct. Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies. Conclusion: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods. But considerable investigation and a clinical study of DES will be required to achieve these goals.
UR - http://www.scopus.com/inward/record.url?scp=70049085839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70049085839&partnerID=8YFLogxK
U2 - 10.1007/s00534-009-0135-1
DO - 10.1007/s00534-009-0135-1
M3 - Article
C2 - 19554255
AN - SCOPUS:70049085839
VL - 16
SP - 628
EP - 632
JO - Journal of Hepato-Biliary-Pancreatic Sciences
JF - Journal of Hepato-Biliary-Pancreatic Sciences
SN - 1868-6974
IS - 5
ER -